# A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection

> **NCT03563742** · PHASE3 · TERMINATED · sponsor: **Janssen Research & Development, LLC** · enrollment: 58 (actual)

## Conditions studied

- Human Immunodeficiency Virus Infections

## Interventions

- **DRUG:** Rilpivirine 25 mg
- **DRUG:** Tenofovir Disoproxil Fumarate (TDF)/Lamivudine (3TC)

## Key facts

- **NCT ID:** NCT03563742
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-09-24
- **Primary completion:** 2021-06-28
- **Final completion:** 2021-06-28
- **Target enrollment:** 58 (ACTUAL)
- **Why stopped:** High SF rate (less treatment-naïve subjects \& subjects with viral load \<100000). Reevaluation in scientific position in India after internal discussion.
- **Last updated:** 2024-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03563742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03563742, "A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03563742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*